Found 7 matching trials
Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
PHASE2The primary purpose of this study is to evaluate the efficacy and safety of...
Location
Shanghai Jiao Tong University Chest Hospital
Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
PHASE2This is a single-arm, exploratory trial to evaluate the efficacy and safety...
Location
Shandong Cancer Hospital and Institute
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
N/AThis observational study aims to evaluate the real-world effectiveness and ...
Location
Peking University Shenzhen Hospital
WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC
PHASE2The aim of this trial is to evaluate the safety of WX-0593 combined with co...
Location
Shandong Cancer Hospital and Institute
Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
PHASE3The primary purpose of this study is to evaluate the efficacy and safety of...
Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
PHASE2The purpose of the study is to evaluate safety and efficacy of WX-0593 oral...
Location
The First Affiliated Hospital of Anhui Medical University
A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients
PHASE1The purpose of the study is to evaluate safety, pharmacokinetics and effica...
Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences